Novartis

This sponsor has funded 77 studies across 56 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
2353 Finalised Yes No
2356 Finalised Yes Yes
2382 Finalised Yes No
2385 Ongoing Yes No
2388 Ongoing Yes No
2561 Ongoing Yes No
2569 Ongoing Yes No
3247 Finalised Yes Yes
3296 Finalised Yes Yes
3335 Finalised Yes Yes
3577 Finalised Yes Yes
4101 Finalised Yes Yes
4207 Finalised Yes Yes
4568 Finalised Yes Yes
4845 Finalised Yes Yes
4963 Finalised Yes Yes
5035 Finalised Yes Yes
5153 Finalised Yes Yes
5914 Ongoing No No
6073 Finalised Yes Yes
6239 Finalised Yes Yes
6338 Finalised No No
6665 Finalised Yes Yes
7201 Finalised Yes Yes
7309 Finalised Yes Yes
7317 Finalised Yes Yes
7325 Finalised Yes Yes
7537 Finalised Yes Yes
7607 Ongoing Yes No
7674 Finalised Yes Yes
7795 Finalised Yes Yes
7828 Finalised Yes Yes
8295 Finalised Yes Yes
8816 Finalised Yes Yes
9073 Planned No No
9076 Finalised Yes Yes
9462 Finalised Yes Yes
10093 Finalised Yes Yes
10165 Planned Yes No
10541 Ongoing Yes No
10649 Finalised Yes Yes
10715 Finalised Yes Yes
10753 Finalised No No
11656 Finalised Yes No
12183 Finalised Yes Yes
12912 Finalised No No
12987 Finalised No No
13054 Finalised Yes Yes
13218 Finalised Yes No
13835 Finalised Yes Yes
13908 Finalised Yes Yes
18214 Ongoing Yes No
18261 Finalised Yes Yes
18358 Ongoing Yes No
25626 Ongoing No No
28059 Finalised Yes Yes
31153 Ongoing Yes No
31405 Planned No No
32497 Ongoing Yes No
36014 Planned Yes No
38736 Planned Yes No
39412 Ongoing Yes No
41010 Planned Yes No
41014 Finalised Yes Yes
41161 Ongoing No No
41495 Planned Yes No
42022 Ongoing Yes No
42905 Ongoing Yes No
44782 Ongoing Yes No
45799 Finalised Yes Yes
45875 Ongoing Yes No
49803 Planned Yes No
49855 Ongoing Yes No
104255 Planned Yes No
104950 Planned Yes No
105374 Ongoing No No
106133 Planned Yes No

PAS by Risk Management Plan (RMP) requirement

Novartis

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.